@RheumNow Dr. John Cush

Dr. John Cush posts on X about $abbv, longterm, health, psa the most. They currently have [------] followers and [----] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

[--] Week [------] -6.40%
[--] Month [------] -6.60%
[--] Months [-------] +62%
[--] Year [-------] -12%

Mentions: [--] #

[--] Week [--] -36%
[--] Month [--] +62%
[--] Months [---] +9.60%
[--] Year [---] +118%

Followers: [------] #

[--] Week [------] +0.10%
[--] Month [------] +0.37%
[--] Months [------] +3.80%
[--] Year [------] +7.90%

CreatorRank: [-------] #

Social Influence

Social category influence stocks countries travel destinations currencies finance technology brands social networks automotive brands celebrities agencies

Social topic influence $abbv #29, longterm, health, psa, pts, aged, novartis #32, vienna, austria, events

Top accounts mentioned or mentioned by @ericdeinmd @richardpaconway @doctorrbc @drdavidkarp @noufahmedalham2 @utswrheum @rwcsmtg @gibsonrheumpac @drdavidliew @acrheum @ebrheum @12 @mcp @mithurheum @gibson_rheumpac @24 @adelacastro222 @philipcrobinson @baseline @3yrs

Top assets mentioned AbbVie Inc (ABBV) Novartis AG (NVS) Sanofi (SNY) Serum (SRM) Flare (FLR) CannabisCoin (CANN) Enzyme (MLN) Calcium (CAL) GOUT (GOUT)

Top Social Posts

Top posts by engagements in the last [--] hours

"PNAS has a novel approach to #RA Tx; bioengineered probiotic(Lactobacillus reuteri) orally delivers a peptide Kv1.3 channel blocker to RxRA. Kv1.3 is expressed on CCR7 effector memory T cells. Blocking Kv1.3 improves RA & PSO in rat models. https://bit.ly/3Y1PTwk https://bit.ly/3Y1PTwk"
X Link 2023-02-02T22:43Z 25.1K followers, [---] engagements

"FAERS retrospective safety study of JAKi use in 75K RA pts (52K Tofa; 21K Upa 2.2K Bari vs bDMARDs) found JAKi had incr risk of VTE (adj ROR=2.11) CVA (ROR=1.25) IHD (1.23) edema(1.22) & tachyarrhythmias (1.15) https://buff.ly/3QSFDVY https://buff.ly/3QSFDVY"
X Link 2024-05-21T20:00Z 24.9K followers, [----] engagements

"FDA adverse event study of JAKi in #RA assoc w/ signif more VTE ischemic heart Dz & tachyarrhythmias. [-----] on JAKi vs [------] on biologics (TNFi RTX TCZ); JAK had more VTE (ROR=2.11) CVA (ROR=1.25) IHD (1.23) arrhythmias (1.15 ) esp in 1st yr. https://buff.ly/4byn9kT https://buff.ly/4byn9kT"
X Link 2024-07-09T16:00Z 24.9K followers, [----] engagements

"FDA adverse event study of JAKi in #RA assoc w/ signif more VTE ischemic heart Dz & tachyarrhythmias. [-----] on JAKi vs [------] on biologics (TNFi RTX TCZ); JAK had more VTE (ROR=2.11) CVA (ROR=1.25) IHD (1.23) arrhythmias (1.15 ) esp in 1st yr. https://buff.ly/3W1A1KD https://buff.ly/3W1A1KD"
X Link 2024-07-13T20:00Z 24.9K followers, [----] engagements

"Turkish retrospective review of [--] axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of 30mo SEC retention was 90% @12 mos & 81% @24 mos. There was only [--] local tumor recurrence w bladder carcinoma https://buff.ly/40byDZz https://buff.ly/40byDZz"
X Link 2024-10-21T16:00Z 24.9K followers, [---] engagements

"Serial MRI study of SI & lumbar (LS) joints in [--] early axSpA (Sxs 5.5yrs) over [--] yrs showed: - SIJ developed bone marrow edema sclerosis & erosion. - LS: fat lesions decreased & erosions increased. - Facet joint inflammation (in t0) significantly influenced yr [--]. LS bony proliferation - Biologics had no effect on MRI changes https://buff.ly/4hu5JtU https://buff.ly/4hu5JtU"
X Link 2024-11-04T19:00Z 24.8K followers, [----] engagements

"Serial MRI study of SI & lumbar (LS) joints in [--] early axSpA (Sxs 5.5yrs) over [--] yrs showed: - SIJ developed bone marrow edema sclerosis & erosion. - LS: fat lesions decreased & erosions increased. - Facet joint inflammation (in t0) significantly influenced yr [--]. LS bony proliferation - Biologics had no effect on MRI changes https://buff.ly/4hGnw12 https://buff.ly/4hGnw12"
X Link 2024-11-09T17:00Z 24.8K followers, [----] engagements

"Adjuvant recombinant zoster vaccine immunogenicity in patients with RA aged [--] years treated with a JAKi. Watch Dr. Kevin Winthrop present 60-week results from a randomized Phase [--] substudy. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/3Eue6H3 https://buff.ly/3Eue6H3"
X Link 2025-02-10T21:00Z 23.4K followers, [---] engagements

"Adela Castro @AdelaCastro222 Multimorbidity in Rheumatoid Arthritis: -Affects 75% of pts -Reduces quality of life and increases mortality -Highly associated w/ D2T RA -Requires multidisciplinary care teams (PCP specialists case management PT) -Management should start early in the disease #RNL2025"
X Link 2025-02-13T21:00Z 23.4K followers, [---] engagements

"EGPA in [----] Eosinophilic Granulomatosis with Polyangiitis (EGPA) the artist formerly known as Churg-Strauss syndrome remains somewhat of a rogue agent among the vasculitides. https://buff.ly/4hZr4ef https://buff.ly/4hZr4ef"
X Link 2025-02-17T16:30Z 23.4K followers, [----] engagements

"📊 PRESENTATION BY DR. KEVIN WINTHROP: Adjuvant recombinant zoster vaccine in patients with RA aged [--] years treated with a JAKi View long-term immunogenicity from a Phase [--] substudy. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/4k59ZBh https://buff.ly/4k59ZBh"
X Link 2025-02-19T15:00Z 23.4K followers, [---] engagements

"Korean insurance claims data shows #RA pts have a higher risk of renal cancer (vs gen. population) unrelated to serostatus. The renal CA risk (aHR 1.34;1.041.78) was higher in women (aHR 1.57); but RA was not assoc w/ risk of CA of bladder prostate or testes https://buff.ly/41lyBhR https://buff.ly/41lyBhR"
X Link 2025-02-20T16:30Z 23.4K followers, [---] engagements

"Adjuvant recombinant zoster vaccine immunogenicity in patients with RA aged [--] years treated with a JAKi. Watch Dr. Kevin Winthrop present 60-week results from a randomized Phase [--] substudy. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/3XvVUDB https://buff.ly/3XvVUDB"
X Link 2025-02-21T16:30Z 23.4K followers, [---] engagements

"Australian population study of [-----] RA pts (68% F; age [--] yrs) vs [-----] controls preexisting cancer (CA) in RA was less prevalent (7.6% vs 14.2%). Cancer incid. rates lower in RA (CIR [-----] vs 24.77) & stable over [--] decades. RA CIR higher for lung (CIR 1.17) & heme CA (CIR 1.21) but lower for most other CA https://buff.ly/3D3bX4C https://buff.ly/3D3bX4C"
X Link 2025-02-21T19:00Z 25.1K followers, [----] engagements

"🔍 Vaccine immunogenicity with JAKi treatment Watch Dr. Kevin Winthrop present long-term immunogenicity of an adjuvant recombinant zoster vaccine in patients aged [--] years with RA receiving a JAKi. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/3Xgdv21 https://buff.ly/3Xgdv21"
X Link 2025-02-25T16:30Z 23.4K followers, [----] engagements

"RNA-seq analysis of human chondrocytes (HTC) shows Osteoarthritis has more HTC-1 (w/ more cell apoptosis & PD-1 genes) & proliferate fibrochondrocytes (ProFC2) w/ heightened inflammatory response & increased cytokine signalling https://buff.ly/3EXvOmw https://buff.ly/3EXvOmw"
X Link 2025-02-26T23:00Z 25.1K followers, [---] engagements

"Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase [--] Trial Sponsored by Amgen https://buff.ly/w9sFiXA https://buff.ly/w9sFiXA"
X Link 2025-03-19T20:00Z 25K followers, [----] engagements

"Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase [--] Trial Sponsored by Amgen https://buff.ly/E5N24kb https://buff.ly/E5N24kb"
X Link 2025-03-22T12:27Z 25.1K followers, [----] engagements

"IBS in America Despite advances IBS remains a burden for many millions. A new AGA-sponsored survey conducted by The Harris Poll a Stagwell (STGW) agency reveals that IBS symptoms disrupt patients productivity and personal activities [--] days each month impacting both personal and professional life. https://buff.ly/KyyTPJq https://buff.ly/KyyTPJq"
X Link 2025-08-14T15:30Z 24.8K followers, [---] engagements

"Anifrolumab appears effective & safe in refractory Cutaneous LE. OL Study of [--] CLE on HCQ topical steroids failed multiple DMARDs. All Rx w/ ANIF [---] mg IV q4wks. ALL improved CLASI-A decr from [--] to [--] (p0.001); CLASI-D decreased from [--] to [--] (p0.001). DBPCT needed https://buff.ly/ApSKwMs https://buff.ly/ApSKwMs"
X Link 2025-08-15T00:00Z 24.9K followers, [----] engagements

"The Patient Journey with Rheumatic Disease Oton and colleagues have reviewed the "patient journey" - from symptoms to specialty referral in those diagnosed with rheumatic and musculoskeletal diseases (RMDs). They identify the eight stages along the way and where improvements are needed. https://buff.ly/OWL1WaG https://buff.ly/OWL1WaG"
X Link 2025-08-18T21:00Z 24.9K followers, [---] engagements

"Methotrexate intolerance in rheumatoid arthritis Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however there is significant intolerance to this drug among adult RA patients - especially at doses above [--] mg per week. https://buff.ly/V5NzgNP https://buff.ly/V5NzgNP"
X Link 2025-08-29T19:00Z 25.1K followers, [----] engagements

"📊 PRESENTED AT EULAR 2025: Long-term safety of a JAKi 📊 View safety across [-----] patient-years of data from [--] Phase [--] trials in adult patients with RA PsA AS or nr-axSpA. This poster is sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/hb6KgN7 https://buff.ly/hb6KgN7"
X Link 2025-08-30T14:00Z 25.1K followers, [---] engagements

"NEW EULAR POSTER: Real-world impact of second-line treatment choice in patients with PsA 🔎View the effectiveness of different PsA treatment patterns: TNFi to JAKi TNFi to IL-17i or TNFi to TNFi. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/8DDr1TQ https://buff.ly/8DDr1TQ"
X Link 2025-08-31T14:00Z 25.1K followers, [---] engagements

"NEW EULAR POSTER: Real-world treatment patterns across the first [--] months of first-line advanced therapy in patients with PsA Compare treatment switching across first-line MOAs and treatments. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/YI6urZv https://buff.ly/YI6urZv"
X Link 2025-08-31T20:00Z 25.1K followers, [---] engagements

"Long-term Lab Monitoring in RA is Inefficient Annals of Internal Medicine has published a retrospective study of long-term routine laboratory toxicity monitoring (lt-RLTM) in patients receiving disease-modifying antirheumatic drug (DMARD) therapy showing that most very abnormal laboratory finding occur early in therapy (first [--] months) or are anticipated or only after dose escalation. https://buff.ly/iCewFEC https://buff.ly/iCewFEC"
X Link 2025-09-02T15:30Z 25.1K followers, [----] engagements

"NEW EULAR [----] POSTER: JAKi safety across [-----] patient-years in adults with RA PsA AS or nr-axSpA 🔍 View the long-term Phase [--] safety of a JAKi. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/FuHQdJ5 https://buff.ly/FuHQdJ5"
X Link 2025-09-03T21:00Z 25.1K followers, [---] engagements

"SMART study from India finally published. RCT compare split-dose to single-dose oral MTX in [---] RA pts. Split dose was superior w/ significantly higher EULAR good response at [--] weeks; & reduced need for 2nd DMARD but had more intolerance and transaminitis. https://buff.ly/Fwci8Sa https://buff.ly/Fwci8Sa"
X Link 2025-09-04T19:53Z 25.1K followers, [----] engagements

"Evidence of immune ageing detected at the earliest stages of RA. Study of [--] controls [--] CSA [--] undiff. arthritis (UA) [--] early RA & [--] DMARD naive RA. UA & CSA had reduced naive CD4 T cells. Th17 Tregs &7 senescent T cells were only seen once RA was established. https://buff.ly/Be6jnYL https://buff.ly/Be6jnYL"
X Link 2025-09-16T00:00Z 25.1K followers, [----] engagements

"Commercial claims analysis of [----] adults w/ axSpA and/or PsA [----] who had joint replacements. JAK inhibitor use did not significantly reduce joint replacement (OR 0.67; 0.411.08) BUT TNFi Non-TNFi biologics & DMARD users had signif fewer surgeries (OR 0.65) vs NSAID users https://buff.ly/ECDfwi8 https://buff.ly/ECDfwi8"
X Link 2025-09-17T21:00Z 25.1K followers, [---] engagements

"📊 PRESENTED AT EULAR 2025: Long-term safety of a JAKi 📊 View safety across [-----] patient-years of data from [--] Phase [--] trials in adult patients with RA PsA AS or nr-axSpA. This poster is sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/JGIx6jy https://buff.ly/JGIx6jy"
X Link 2025-10-01T02:42Z 24.7K followers, [---] engagements

"A JAKi in RA: Explore the Data Guide 👀 Dr. Curtis and Dr. Winthrop share best practices for preparing to discuss risk in RA including a new long-term efficacy and safety data visualization tool. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/fbbVc8h https://buff.ly/fbbVc8h"
X Link 2025-10-06T14:00Z 24.8K followers, [---] engagements

"Optimizing DMARD Therapy in Rheumatoid Arthritis A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible with a low risk of flare. https://buff.ly/uswAFw3 https://buff.ly/uswAFw3"
X Link 2025-10-08T15:30Z 25.1K followers, [---] engagements

"Not all difficult-to-treat RA will have rapid radiographic progression A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy. https://buff.ly/qPHUnCy https://buff.ly/qPHUnCy"
X Link 2025-10-08T22:30Z 24.9K followers, [----] engagements

"💬A JAKi CHAT: Shared Decision-Making in RA Dr. Curtis and Dr. Winthrop discuss approaches to patient conversations on risk with uncontrolled RA and treatment considerations including JAKi safety. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/fbbVc8h https://buff.ly/fbbVc8h"
X Link 2025-10-09T15:30Z 24.7K followers, [---] engagements

"Prediction of D2T-RA. Model was trained on BRASS pts (700; 16% w/ D2T-RA) & validated on CERTAIN pts (2070; 28% D2TRA). PRO's were strongest predictors. Moderate predictive accuracy (C-index of [----] & 0.62) w/ functional status pain fatigue and global Dz activity https://buff.ly/lXM9WZB https://buff.ly/lXM9WZB"
X Link 2025-10-09T21:57Z 24.9K followers, [---] engagements

"📊 NEW FROM EULAR: How many patients with PsA switch from their first-line treatment in the first year 📊 Explore real-world switching patterns among PsA patients on first-line advanced therapies. Sponsored by AbbVie Medical Affairs + Health Impact https://buff.ly/rebFHhg https://buff.ly/rebFHhg"
X Link 2025-10-10T15:30Z 24.7K followers, [---] engagements

"Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8 https://buff.ly/TCc6Kc8"
X Link 2025-10-13T19:00Z 24.9K followers, [----] engagements

"📊 NEW FROM EULAR: Real-world effectiveness of switching to a JAKi after first-line TNFi in PsA See how second-line treatment choices impacted TJC and SJC in patients from the Adelphi database. Poster sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/AuFE8FS https://buff.ly/AuFE8FS"
X Link 2025-10-14T14:00Z 24.8K followers, [---] engagements

"Tertiary center study of [---] GPA pts (age [--] [--] mos F/U) - total of [--] deaths& [---] relapses (in [---] pts;1.53/pt). Predictors of relapse (2 fold incr) = Age [--] male creatinine & CNS dz. Mortality assoc w/ [--] yrs male creatinine [---] CNS @baseline https://buff.ly/5OVa8mL https://buff.ly/5OVa8mL"
X Link 2025-10-14T19:00Z 24.8K followers, [---] engagements

"A JAKi in RA: Explore the Data Guide 👀 Dr. Curtis and Dr. Winthrop share best practices for preparing to discuss risk in RA including a new long-term efficacy and safety data visualization tool. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/Z0YdVvG https://buff.ly/Z0YdVvG"
X Link 2025-10-15T17:00Z 24.8K followers, [---] engagements

"📊 PRESENTED AT EULAR 2025: Long-term safety of a JAKi 📊 View safety across [-----] patient-years of data from [--] Phase [--] trials in adult patients with RA PsA AS or nr-axSpA. This poster is sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/66pYrVt https://buff.ly/66pYrVt"
X Link 2025-10-16T14:01Z 24.8K followers, [---] engagements

"Muscle mass & JAKi [--] active RA pts (+ sarcopenia risk) Rx w/ tofacitinib - signif. improved @1 mo. @6 mos muscle mass signif improved (+242 cm3 +4% p=0017) less w/ NSAIDs); w/ signif creatinine incr (0.06 mg/dl) & decr in serum IL-6 IL-1 & TNF. No change in CK myoglobin LDH AST https://buff.ly/Li3BVUx https://buff.ly/Li3BVUx"
X Link 2025-10-17T00:01Z 24.9K followers, [---] engagements

"💬A JAKi CHAT: Shared Decision-Making in RA Dr. Curtis and Dr. Winthrop discuss approaches to patient conversations on risk with uncontrolled RA and treatment considerations including JAKi safety. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/Z0YdVvG https://buff.ly/Z0YdVvG"
X Link 2025-10-18T14:06Z 24.8K followers, [---] engagements

"NEW EULAR POSTER: Real-world impact of second-line treatment choice in patients with PsA 🔎View the effectiveness of different PsA treatment patterns: TNFi to JAKi TNFi to IL-17i or TNFi to TNFi. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/AuFE8FS https://buff.ly/AuFE8FS"
X Link 2025-10-20T19:03Z 24.8K followers, [---] engagements

"A JAKi in RA: Explore the Data Guide 👀 Dr. Curtis and Dr. Winthrop share best practices for preparing to discuss risk in RA including a new long-term efficacy and safety data visualization tool. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/Z0YdVvG https://buff.ly/Z0YdVvG"
X Link 2025-10-21T17:00Z 24.8K followers, [---] engagements

"Study from Czech ATTRA registry of [----] RA pts [---] (7.5%) met criteria for D2T-RA & [----] achieved remission (21%). D2T-RA predicted by machine learning models (accuracy 0.6060.747 AUC 0.6560.832). Predictors included CDAI DAS28-ESR TJC HAQ CRP steroids https://buff.ly/LSMLoV9 https://buff.ly/LSMLoV9"
X Link 2025-10-21T19:00Z 24.9K followers, [---] engagements

"Phase 3b/4 head-to-head SELECT-SWITCH study tested Humira vs Rinvoq in [---] RA MTX pts failing a TNFi then Rx w/ ADA vs UPA x12 wks. UPA ADA w/ DAS28-CRP [---] (43% vs 22%; p0.001) and also for DAS28-CRP [---] (28% vs 14%). No new safety signals https://buff.ly/sQIjg6f https://buff.ly/sQIjg6f"
X Link 2025-10-21T21:46Z 24.8K followers, [---] engagements

"UK National Joint Registry study of [---] million TKR and THA (2010 to 2022); trends show median Length of hosp stay (LOS) decreased from 4.3d to [----] d for THR; & from 4.35d to 2.9d for TKR; & from 3.2d to 1.9d for UKR (unilat. knee replacement). Longer LOS with comorbidity obesity male sex affluence. https://buff.ly/cBGzjzB https://buff.ly/cBGzjzB"
X Link 2025-10-21T22:30Z 24.9K followers, [---] engagements

"Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen. Recommendation based on TULIP-SC Phase III trial. https://buff.ly/n2lPNjx https://buff.ly/n2lPNjx"
X Link 2025-10-22T14:00Z 24.8K followers, [----] engagements

"NEW EULAR POSTER: Real-world treatment patterns across the first [--] months of first-line advanced therapy in patients with PsA Compare treatment switching across first-line MOAs and treatments. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/yAztQdG https://buff.ly/yAztQdG"
X Link 2025-10-23T00:00Z 24.9K followers, [---] engagements

"💬A JAKi CHAT: Shared Decision-Making in RA Dr. Curtis and Dr. Winthrop discuss approaches to patient conversations on risk with uncontrolled RA and treatment considerations including JAKi safety. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/Z0YdVvG https://buff.ly/Z0YdVvG"
X Link 2025-10-23T17:01Z 24.8K followers, [---] engagements

"SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control such as cardioprotective and nephroprotective effects and modest weight loss. A recent study also suggests they may have immunomodulatory effects and prevent autoimmune disease. https://buff.ly/dE2Poex https://buff.ly/dE2Poex"
X Link 2025-10-23T22:30Z 24.8K followers, [----] engagements

"REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://buff.ly/8NDmyCc https://buff.ly/8NDmyCc"
X Link 2025-10-24T14:00Z 24.9K followers, [----] engagements

"NEW EULAR [----] POSTER: JAKi safety across [-----] patient-years in adults with RA PsA AS or nr-axSpA 🔍 View the long-term Phase [--] safety of a JAKi. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/oQkGe00 https://buff.ly/oQkGe00"
X Link 2025-10-24T17:01Z 24.9K followers, [---] engagements

"A JAKi in RA: Explore the Data Guide 👀 Dr. Curtis and Dr. Winthrop share best practices for preparing to discuss risk in RA including a new long-term efficacy and safety data visualization tool. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/E7s7DOu https://buff.ly/E7s7DOu"
X Link 2025-10-25T14:00Z 24.9K followers, [---] engagements

"RheumNows expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb Novartis and UCB. All coverage content is independently selected by RheumNow and its faculty"
X Link 2025-10-26T12:00Z 24.9K followers, [---] engagements

"RheumNows expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb Novartis and UCB. All coverage content is independently selected by RheumNow and its faculty"
X Link 2025-10-26T16:00Z 24.9K followers, [---] engagements

"RheumNows expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb Novartis and UCB. All coverage content is independently selected by RheumNow and its faculty"
X Link 2025-10-26T20:00Z 24.9K followers, [---] engagements

"SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control such as cardioprotective and nephroprotective effects and modest weight loss. A recent study also suggests they may have immunomodulatory effects and prevent autoimmune disease. https://buff.ly/JImN1ec https://buff.ly/JImN1ec"
X Link 2025-10-26T22:00Z 24.8K followers, [----] engagements

"REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://buff.ly/15x3oVD https://buff.ly/15x3oVD"
X Link 2025-10-27T15:30Z 24.8K followers, [---] engagements

"RheumNows expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb Novartis and UCB. All coverage content is independently selected by RheumNow & its faculty"
X Link 2025-10-27T20:00Z 24.9K followers, [---] engagements

"RheumNows expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb Novartis and UCB. All coverage content is selected by RheumNow and its faculty"
X Link 2025-10-28T18:11Z 24.9K followers, [---] engagements

"📊 NEW FROM EULAR: Real-world effectiveness of switching to a JAKi after first-line TNFi in PsA See how second-line treatment choices impacted TJC and SJC in patients from the Adelphi database. Poster sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/6pfosds https://buff.ly/6pfosds"
X Link 2025-10-29T13:30Z 24.9K followers, [---] engagements

"Older Adults Underrepresented in RCTs Drs. Jiha Lee and Sebastian Sattui discuss abstract [----] "Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review" presented at #ACR25 https://buff.ly/oIfUmk6 https://buff.ly/oIfUmk6"
X Link 2025-10-29T19:00Z 24.8K followers, [---] engagements

"RheumNows expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb Novartis and UCB. All coverage content is selected by RheumNow and its faculty"
X Link 2025-10-29T22:58Z 24.8K followers, [---] engagements

"📊 NEW FROM EULAR: How many patients with PsA switch from their first-line treatment in the first year 📊 Explore real-world switching patterns among PsA patients on first-line advanced therapies. Sponsored by AbbVie Medical Affairs + Health Impact https://buff.ly/bILLYZu https://buff.ly/bILLYZu"
X Link 2025-10-30T12:00Z 24.8K followers, [---] engagements

"From Fitbit to first diagnosis: AI is rewriting the RA playbook Two studies presented at this years #ACR25 meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden. https://buff.ly/290TP0h https://buff.ly/290TP0h"
X Link 2025-10-30T18:00Z 24.9K followers, [---] engagements

"RheumNows coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb Novartis and UCB. All coverage content is selected by RheumNow and its faculty"
X Link 2025-10-30T21:03Z 24.9K followers, [---] engagements

"💬A JAKi CHAT: Shared Decision-Making in RA Dr. Curtis and Dr. Winthrop discuss approaches to patient conversations on risk with uncontrolled RA and treatment considerations including JAKi safety. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/E7s7DOu https://buff.ly/E7s7DOu"
X Link 2025-10-31T16:00Z 24.9K followers, [---] engagements

"Rheumatoid arthritis and the big bang at #ACR25 Is there bang for the buck using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs TNFi and JAKi in RA https://buff.ly/kgMODg4 https://buff.ly/kgMODg4"
X Link 2025-10-31T18:00Z 24.8K followers, [---] engagements

"📖➡The GCA story continues with new data from a Phase [--] trial of a JAKi sponsored by AbbVie Medical Affairs + Health Impact. 🔥 Hot off the press from ACR [----] hear Dr. Dua & Dr. Boone discuss the latest data in GCA. https://buff.ly/8jh3l1m https://buff.ly/8jh3l1m"
X Link 2025-11-03T17:00Z 24.9K followers, [---] engagements

"Two years of a JAKi in GCA 📊 Dr. Dua and Dr. Boone share their thoughts on the latest data from a Phase [--] trial with a JAKi in GCA including key long-term efficacy and safety outcomes. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/8jh3l1m https://buff.ly/8jh3l1m"
X Link 2025-11-05T20:00Z 24.9K followers, [---] engagements

"Using AI and LLMs in Qualitative Data Dr. Bella Mehta discusses abstract [----] (Using AI to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models) presented at #ACR25 https://buff.ly/4LjRmOP https://buff.ly/4LjRmOP"
X Link 2025-11-06T15:01Z 24.9K followers, [---] engagements

"Explore 2-year data from a JAKi in GCA 👀 Dr. Dua and Dr. Boone discuss remission flares glucocorticoid use and safety outcomes from the Phase [--] trial of a JAKi in GCA. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/8jh3l1m https://buff.ly/8jh3l1m"
X Link 2025-11-06T19:00Z 24.9K followers, [---] engagements

"📖➡The GCA story continues with new data from a Phase [--] trial of a JAKi sponsored by AbbVie Medical Affairs + Health Impact. 🔥 Hot off the press from ACR [----] hear Dr. Dua & Dr. Boone discuss the latest data in GCA. https://buff.ly/NiPzclF https://buff.ly/NiPzclF"
X Link 2025-11-10T15:00Z 24.9K followers, [---] engagements

"Off the Shelf: CAR-T Dr. Akhil Sood reports on abstract [----] (iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy) presented at#ACR25. https://buff.ly/T2omgTU https://buff.ly/T2omgTU"
X Link 2025-11-10T18:00Z 24.9K followers, [---] engagements

"RETREAT study was a [--] wk RCT of Tai Chi in [---] knee OA pts Rx w/ online OA info vs same plus free web based tai chi video program. Tai Chi group had signif improved knee pain (2.7 v -1.2); (12 v 6.9) & achieved a minimal pain & function (73% v 47%); and Its free https://buff.ly/CtRDVnt https://buff.ly/CtRDVnt"
X Link 2025-11-10T18:24Z 24.9K followers, [---] engagements

"In [----] [--] pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff fever & Hi CRP/ESR - none had hip pain. 4/5 were male w/ mean age of [--] yrs. None were RF/CCP+ https://buff.ly/TnpcWIA https://buff.ly/TnpcWIA"
X Link 2025-11-10T23:30Z 24.9K followers, [----] engagements

"IL-23 Blockade Goes Oral A new player is entering the IL-23 arena and its a tablet Icotrokinra (ICO) a first-in-class peptide that binds and blocks the IL-23R is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies. https://buff.ly/nVPuCeh https://buff.ly/nVPuCeh"
X Link 2025-11-11T15:00Z 24.9K followers, [---] engagements

"Two years of a JAKi in GCA 📊 Dr. Dua and Dr. Boone share their thoughts on the latest data from a Phase [--] trial with a JAKi in GCA including key long-term efficacy and safety outcomes. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/NiPzclF https://buff.ly/NiPzclF"
X Link 2025-11-12T15:00Z 24.9K followers, [---] engagements

"Western Australia study of [----] SLE pts (median [--] yrs old). Interstitial lung disease was seen in in 3.8% of SLE [--] fold more than controls. Risk factors for ILD included older age smoking and serositis. SLE-ILD pts had higher mortality rates (MR [----] CI 37.071.1). https://buff.ly/jtTXa0l https://buff.ly/jtTXa0l"
X Link 2025-11-13T16:30Z 24.9K followers, [---] engagements

"Deep Learning Model Accurately Detects Ankylosing Spondylitis on MRI AI continues to move from research labs into rheumatology clinics promising to reshape how inflammatory diseases are diagnosed and monitored. AS in particular poses a diagnostic challengeits early imaging findings are subtle and radiographic changes may take years to appear and require specific musculoskeletal radiology expertise which may not be universally available. A new deep learning model ASembleNet offers a glimpse into how AI could bridge this diagnostic gap. https://buff.ly/1knZtFQ https://buff.ly/1knZtFQ"
X Link 2025-11-13T17:00Z 24.9K followers, [---] engagements

"IL-1 Inhibition in CPPD Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra an interleukin-1 inhibitor is a promising alternative for patients with acute CPPD flares. https://buff.ly/aHYVJnV https://buff.ly/aHYVJnV"
X Link 2025-11-13T23:30Z 24.9K followers, [---] engagements

"SLE Prospect. Observational Study of [---] SLE pts over [--] yr for outcomes& IFN signature (IFNGS). 71% were IFNGS-high. IFNGS-high pts were younger. on GC w/ Hi SLEDAI-2K. SLEDAI-2K decreased over time regardless of IFNGS. By 36mos 45% had [--] flare; higher in IFNGS. https://buff.ly/aYGEVq9 https://buff.ly/aYGEVq9"
X Link 2025-11-14T01:00Z 24.9K followers, [---] engagements

"Putting Steroid Tapering into Practice in SLE Drs. Yuz Yusof and Ed Vital discuss abstract [----] (Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project) presented at #ACR25. https://buff.ly/RgTJdAB https://buff.ly/RgTJdAB"
X Link 2025-11-14T19:00Z 24.9K followers, [---] engagements

"GLP-1 Receptor Agonists in PsA: Mortality and MACE Dr. Antoni Chan reports on abstract [----] (Mortality and Major Adverse Cardiac Events (MACE) with GLP-1 Receptor Agonists in Psoriatic Arthritis) presented at #ACR25. https://buff.ly/6lEBtOB https://buff.ly/6lEBtOB"
X Link 2025-11-14T21:00Z 24.9K followers, [---] engagements

"Explore 2-year data from a JAKi in GCA 👀 Dr. Dua and Dr. Boone discuss remission flares glucocorticoid use and safety outcomes from the Phase [--] trial of a JAKi in GCA. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/NiPzclF https://buff.ly/NiPzclF"
X Link 2025-11-15T15:00Z 24.9K followers, [---] engagements

"20-40% of Autoimmune hepatitis (AIH) is associated with other autoimmune diseases - lead by autoimmune thyroiditis type [--] DM ulcerative colitis Crohn disease & celiac (but less so for RA PBC SLE Sjgren syndrome vitiligo). AIH Dx Abs include ANA ASMA LKM1. https://buff.ly/MMqe3B6 https://buff.ly/MMqe3B6"
X Link 2025-11-15T21:00Z 24.9K followers, [----] engagements

"A JAKi in GCA: 2-year efficacy and safety results in a Phase [--] study Discover how continued treatment with a JAKi impacted disease remission and steroid use. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/9yUSBWu https://buff.ly/9yUSBWu"
X Link 2025-11-16T17:00Z 24.9K followers, [---] engagements

"In [----] [--] pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff fever & Hi CRP/ESR - none had hip pain. 4/5 were male w/ mean age of [--] yrs. None were RF/CCP+ https://buff.ly/9oBF78e https://buff.ly/9oBF78e"
X Link 2025-11-17T18:01Z 24.9K followers, [----] engagements

"Hospital Mortality in Dermatomyositis A cohort study reveals that hospitalized patients with dermatomyositis have a higher in-hospital mortality rate in the presence of active rash interstitial lung disease and an elevated neutrophil-to-lymphocyte ratio at admission. https://buff.ly/1xNMOVT https://buff.ly/1xNMOVT"
X Link 2025-11-17T21:00Z 24.9K followers, [---] engagements

"Can EMR Treatment Suggestions Improve Decision Making In a new study researchers from Northwestern University and the University of Sydney identified a sweet spot in clinical decision-making. By presenting just the right number of treatment alternatives in the EHR system physicians were more likely to choose a high-quality alternative rather than defaulting to the status quo. https://buff.ly/picHcmx https://buff.ly/picHcmx"
X Link 2025-11-17T23:30Z 24.9K followers, [---] engagements

"📖➡The GCA story continues with new data from a Phase [--] trial of a JAKi sponsored by AbbVie Medical Affairs + Health Impact. 🔥 Hot off the press from ACR [----] hear Dr. Dua & Dr. Boone discuss the latest data in GCA. https://buff.ly/NiPzclF https://buff.ly/NiPzclF"
X Link 2025-11-18T18:01Z 24.9K followers, [---] engagements

"PROSPERO meta-analysis shows an effect of diet on #RA risk. [--] independent studies (n=270121) showed a reduced risk of incident RA with Anti-inflammatory (OR 0.56; 0.310.99) Mediterranean (OR 0.88; 0.780.99) and HEI (OR 0.60; 0.251.47) but not DASH diets https://buff.ly/lNp7m2U https://buff.ly/lNp7m2U"
X Link 2025-11-18T21:00Z 24.9K followers, [----] engagements

"NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA Click to see the latest results from a Phase [--] trial presented at ACR [----] sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/9yUSBWu https://buff.ly/9yUSBWu"
X Link 2025-11-19T18:01Z 24.9K followers, [---] engagements

"Two years of a JAKi in GCA 📊 Dr. Dua and Dr. Boone share their thoughts on the latest data from a Phase [--] trial with a JAKi in GCA including key long-term efficacy and safety outcomes. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/NiPzclF https://buff.ly/NiPzclF"
X Link 2025-11-20T16:30Z 24.9K followers, [---] engagements

"25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging [--] years researchers said. https://buff.ly/P05kLYj https://buff.ly/P05kLYj"
X Link 2025-11-20T21:00Z 24.9K followers, [----] engagements

"Myelodysplastic & chr myelomonocytic leukemia pts rarely get lupus. Review of [--] w/ SLE & [--] w/ CLE; these were older (65 yrs) more male (15M/9F) w/ less renal 10% & articular 36% Dz w/ less dsDNA 32%. Thought to be clonal inflammatory & not autoinflammatory process. LE therapies were ineffective but azacitidine or allogeneic HSCT effective in 5/7. https://buff.ly/Z9I5r67 https://buff.ly/Z9I5r67"
X Link 2025-11-21T01:00Z 24.9K followers, [---] engagements

"Study of [------] UK Biobank participants (40 to 69yrs) betw [--------] showed incident RA in [----]. Having self reported eating disorders (anorexia nervosa bulimia etc) was associated with a higher risk of developing RA (ad HR 1.76; 1.122.76) moreso in men (HR 5.09). https://buff.ly/clR4QZL https://buff.ly/clR4QZL"
X Link 2025-11-21T15:01Z 24.9K followers, [---] engagements

"Rheumatology Supply and Demand (2009 - 2024) A retrospective review of US rheumatology manpower and training from 2009- [--] shows that US rheumatology training has become competitive with an increasing surplus of applicants compared to available training positions. https://buff.ly/WLsm3jf https://buff.ly/WLsm3jf"
X Link 2025-11-21T21:00Z 24.9K followers, [----] engagements

"No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of [--] [---] ipts Rx IL-17(R)Ai and [---] MACEs. MACE risk was not elevated (OR [----] 95% CI 0.75-2.08 vs TNF- inhibitors. https://buff.ly/wWosTiv https://buff.ly/wWosTiv"
X Link 2025-11-22T17:00Z 24.9K followers, [---] engagements

"Retrospective cohort study adult RA patients shows that TRIPLE Positivity (RF + /ACPA + /ANA +) was consistently associated with higher disease activity at baseline and [--] months of follow-up and lower rates of sustained remission compared to RF + /ACPA + /ANA- https://buff.ly/yAZTea8 https://buff.ly/yAZTea8"
X Link 2025-11-22T23:00Z 24.9K followers, [----] engagements

"Explore 2-year data from a JAKi in GCA 👀 Dr. Dua and Dr. Boone discuss remission flares glucocorticoid use and safety outcomes from the Phase [--] trial of a JAKi in GCA. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/NiPzclF https://buff.ly/NiPzclF"
X Link 2025-11-23T21:00Z 24.9K followers, [---] engagements

"Lupus Nephritis study of [---] pts followed [---] mos. Median time to wean GC to [---] mg/day [--] mg/day & D/C was [--] [--] & [--] months post-Dx. Predictors of shorter time to D/C= Sustained CR/SLEDAI-2K4 membranous LN & HCQ. Prolonged GC & renal flares increase damage accrual https://buff.ly/p9BtUR0 https://buff.ly/p9BtUR0"
X Link 2025-11-23T23:00Z 24.9K followers, [----] engagements

"A New Disease Activity Score for Antiphospholipid Syndrome APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features causing obstetric as well as thrombotic microvascular and non-thrombotic (TMN) symptoms. https://buff.ly/o0GUN7b https://buff.ly/o0GUN7b"
X Link 2025-11-24T18:00Z 24.9K followers, [----] engagements

"Retrospective study of [--] pts w/ MDA5 + DM-ILD Rx w baricitinib. [--] (79.5%) had improvement in Gottrons heliotrope dyspnea HRCT score ferritin LDH steroid dose & [--] mo survival (87% vs. 70%p = 0.047). https://buff.ly/ENWEQsl https://buff.ly/ENWEQsl"
X Link 2025-11-25T18:00Z 24.9K followers, [---] engagements

"NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA Click to see the latest results from a Phase [--] trial presented at ACR [----] sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/WyTD5sV https://buff.ly/WyTD5sV"
X Link 2025-11-25T23:30Z 24.9K followers, [---] engagements

"📖➡The GCA story continues with new data from a Phase [--] trial of a JAKi sponsored by AbbVie Medical Affairs + Health Impact. 🔥 Hot off the press from ACR [----] hear Dr. Dua & Dr. Boone discuss the latest data in GCA. https://buff.ly/NCxUfvI https://buff.ly/NCxUfvI"
X Link 2025-11-26T18:00Z 24.9K followers, [---] engagements

"Partial vs Total Knee Replacement: Is One Superior Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after [--] years in a randomized trial -- and maybe a little bit better. https://buff.ly/T6Bscs9 https://buff.ly/T6Bscs9"
X Link 2025-11-26T21:00Z 24.9K followers, [----] engagements

"Tuesday Nite Rheumatology (on 11.18.25) Replay of RheumNow Live [----] - Spondyloarthritis Sponsored by AbbVie Featuring: Dr. Desiree van der Heidje - Advances in Treatment of Spondyloarthritis Dr. Jennifer Cather - Progress in Hidradenitis Supprativa Dr. Catherine Bakewell - Imaging Evaluation of Spondyloarthritis https://buff.ly/G2UdPhz https://buff.ly/G2UdPhz"
X Link 2025-11-26T23:30Z 24.9K followers, [---] engagements

"Study of [----] dermatomyositis (DM) & polymyositis (PM) pts looked at short term (ST: [--] mos) vs long term (LT) steroid (GC) use. Vs ST LT GC use assoc w/ higher risks of heart failure (adj OR 1.8) osteoporosis (1.9) all-cause & PM/DM-related admission (3.8) & higher costs https://buff.ly/iWqIUQf https://buff.ly/iWqIUQf"
X Link 2025-11-27T18:00Z 24.9K followers, [---] engagements

"Chronic pain may dramatically raise your blood pressure Widespread chronic pain may stealthily drive up blood pressure partly through its ties to depression and inflammation. https://buff.ly/BMdCM8e https://buff.ly/BMdCM8e"
X Link 2025-11-28T18:00Z 24.9K followers, [---] engagements

"Study of [---] #PsA pts who failed 1st line TNFi Rx (LOE) - [---] Cycled to another TNFi vs [---] Swapped to an IL-17i. Higher Retention in Swap (78%) vs cycled (68%) PsA pts (p 0.001) @12 mos (60 v 40%@3yrs). Tx failure predicted by cycling Dz Activity Rx year axial & mixed involvement (p =0.001). https://buff.ly/aL3MLzA https://buff.ly/aL3MLzA"
X Link 2025-11-28T22:36Z 24.9K followers, [---] engagements

"Partial vs Total Knee Replacement: Is One Superior Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after [--] years in a randomized trial -- and maybe a little bit better. https://buff.ly/jWloxEd https://buff.ly/jWloxEd"
X Link 2025-11-29T23:00Z 24.9K followers, [---] engagements

"Two years of a JAKi in GCA 📊 Dr. Dua and Dr. Boone share their thoughts on the latest data from a Phase [--] trial with a JAKi in GCA including key long-term efficacy and safety outcomes. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/NCxUfvI https://buff.ly/NCxUfvI"
X Link 2025-12-01T15:00Z 24.9K followers, [---] engagements

"Congratulations to Professor Stuart Ralston (Versus Arthritis Professor of Rheumatology) from the University of Edinburgh. He has been honored with the RSE Sir James Black Medal by The Royal Society of Edinburgh for his research research & dedication to medical education https://buff.ly/JLzz1Vr https://buff.ly/JLzz1Vr"
X Link 2025-12-01T23:02Z 24.9K followers, [---] engagements

"Scandinavian study of [----] million PYs shows NO increased risk of myositis after SARS-CoV-2 (mRNA & adenoviral vector) vaccines. Data from [---] myositis events in [----] [---] unvaccinated PYs. Adj IRR 180d risk was [----] (0.631.11) and [----] (0.722.36) respectively https://buff.ly/gu886ZP https://buff.ly/gu886ZP"
X Link 2025-12-02T15:01Z 24.9K followers, [----] engagements

"Fast Facts About Rheumatologist Compensation 2025: - Rheum among lowest paid ($284k) - [----] salaries rose 2% - 53% say theyre underpaid - 41% supplement their income - 6/10 recv incentive bonuses https://buff.ly/satK3Xu https://buff.ly/satK3Xu"
X Link 2025-12-03T21:00Z 25.1K followers, [---] engagements

"DMARD Treatment Lags for Minority Groups with Rheumatoid Arthritis Use of disease-modifying anti-rheumatic drugs (DMARDs) for RA was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients analysis of federal survey data indicated even after adjusting for income education and other factors. https://buff.ly/1M0Jwfw https://buff.ly/1M0Jwfw"
X Link 2025-12-09T15:01Z 25.1K followers, [---] engagements

"RHEUM Survey What is the Sensitivity of the ANA test 55% 65% 95% 80% 55% 65% 95% 80%"
X Link 2025-12-10T16:42Z 24.9K followers, [---] engagements

"Simple low-cost strategy to Dx/Prognose GCA using CBC components NLR & PLR. [---] GCA vs [---] non-GCA pts - All CBC biomarkers signif assoc w/ ESR & CRP but ESR/CRP did not predict mortality over time; YET mortality signif predicted by PLR NLR MLR (P value 0.044) https://buff.ly/T9ZuaaU https://buff.ly/T9ZuaaU"
X Link 2025-12-10T18:00Z 25.1K followers, [---] engagements

"APP QD Clinic: Difficult AxSpA Philip Mease MD and Christy Vath PA-C Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://buff.ly/8mxQO5E https://buff.ly/8mxQO5E"
X Link 2025-12-10T23:30Z 24.9K followers, [---] engagements

"The countdown is on Drs. Jack Cush & Artie Kavanaugh are previewing whats coming to RheumNow Live [----] in Dallas (Feb 78) and you dont want FOMO on this one. ✅ Register now at 🔥Early bird pricing ends December [--] Get the inside scoop on whats ahead and lock in your spot now. https://buff.ly/aZajbq8 http://RheumNow.Live http://RheumNow.Live https://buff.ly/aZajbq8 http://RheumNow.Live http://RheumNow.Live"
X Link 2025-12-11T01:00Z 24.9K followers, [---] engagements

"APP QD Clinic: Difficult AxSpA Philip Mease MD and Christy Vath PA-C Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://buff.ly/ZfTclq0 https://buff.ly/ZfTclq0"
X Link 2025-12-14T21:00Z 24.9K followers, [---] engagements

"Top [--] States to Practice Rheumatology [--] North Dakota [--] Wisconsin [--] Alaska [--] Montana [--] South Dakota [--] Nebraska [--] Minnesota [--] Washington [--] Utah [--] Maine https://buff.ly/fztDphd https://buff.ly/fztDphd"
X Link 2025-12-16T15:00Z 24.9K followers, [---] engagements

"NEW FROM ACR: See data for patients with RA who achieved remission at [--] months with a JAKi and maintained response at [--] years in a real-world study. Click to learn more about long-term outcomes. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/2AGmUsj https://buff.ly/2AGmUsj"
X Link 2025-12-16T18:00Z 25.1K followers, [---] engagements

"Does GC tapering impact serious infections in patients treated with a JAKi This is your chance to see the latest 52-week safety findings from this Phase [--] study. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/EJJi1Sm https://buff.ly/EJJi1Sm"
X Link 2025-12-17T15:01Z 25K followers, [---] engagements

"76 PsA pts asked [--] questions submitted to Chat-GPT4 & [--] specialists. Answers were scored (accuracy completeness). Both equally accurate ChatGPT scored lower in completeness. Other pts reviewed answers; they preferred ChatGPT 49% vs clinician 34%. ChatGPT was more readable. Questions about progn/comorbidiy (71%) therapy (63%) risks (50%). https://buff.ly/ktXWPuq https://buff.ly/ktXWPuq"
X Link 2025-12-17T21:00Z 24.9K followers, [---] engagements

"Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & [---] Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s higher SDAI & CDAI. https://buff.ly/Drrovfq https://buff.ly/Drrovfq"
X Link 2025-12-18T16:30Z 25K followers, [---] engagements

"Recent study shows that betw 2018-2023 # of Concierge medicine practices in the USA has increased 78.4% (3935 to 7021); mostly in Texas (402) California (387) Florida (352) Georgia (139). Notably a signif growth of corporate owned practices increased from 9.2% to https://buff.ly/KNl079x https://buff.ly/KNl079x"
X Link 2025-12-18T22:01Z 24.9K followers, [---] engagements

"Lilly announced phase [--] RCT TRIUMPH-4 where Retatrutide a new GIP GLP-1 & glucagon recpt agonist was given to obese (BMI 35) knee osteoarthritis pts without diabetes. Wt loss at [--] wks was 28.7% with reduced WOMAC pain scores of [----] points (75.8%) https://buff.ly/uxLpnmD https://buff.ly/uxLpnmD"
X Link 2025-12-19T15:01Z 25.1K followers, [----] engagements

"FDA has approved nerandomilast (Jascayd) for the treatment of progressive pulmonary fibrosis (PPF) in adults based on the results of the phase [--] FIBRONEER trial. Nerandomilast is PDE4 inhibitor in Oct [----] it was approved for use in diopathic pulmonary fibrosis (IPF) https://buff.ly/uWMxY7F https://buff.ly/uWMxY7F"
X Link 2025-12-20T20:56Z 25K followers, [----] engagements

"Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & [---] Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s higher SDAI & CDAI. https://buff.ly/JXmib91 https://buff.ly/JXmib91"
X Link 2025-12-21T15:00Z 25.1K followers, [----] engagements

"GC dose and tapering may influence serious infection risk in patients with GCA. Discover the key safety outcomes observed during a year of JAKi therapy in a Phase [--] trial. Sponsored by AbbVie Medical Affairs +Health Impact. https://buff.ly/EJJi1Sm https://buff.ly/EJJi1Sm"
X Link 2025-12-22T15:00Z 25.1K followers, [---] engagements

"Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Stills disease (AOSD). https://buff.ly/rGUvtYL https://buff.ly/rGUvtYL"
X Link 2025-12-22T23:30Z 25K followers, [----] engagements

"Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis The FDA has approved nerandomilast (Jascayd) a PDE4b inhibitor to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October [----]. https://buff.ly/OslWbX4 https://buff.ly/OslWbX4"
X Link 2025-12-24T16:30Z 25.1K followers, [----] engagements

"BREAKING NEWS: How many patients with RA achieve and maintain remission with a JAKi Find out in the RheumNow poster hall with data from the latest real- world study of long-term RA remission. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/2AGmUsj https://buff.ly/2AGmUsj"
X Link 2025-12-24T18:01Z 25.1K followers, [---] engagements

"Review of IL-1 family cytokines in inflammation and immunity - including IL-1 IL-18 IL-33 IL-36 IL-37 IL-38 IL-1Ra etc. Full read -- Good Reference https://buff.ly/jmT18rl https://buff.ly/jmT18rl"
X Link 2025-12-24T23:30Z 25.1K followers, 34.9K engagements

"EULAR Classification criteria for hemachromatosis presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3 & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025"
X Link 2025-12-25T01:00Z 25K followers, [----] engagements

"Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕ Clinical approach 📋 What rheums need to know Download & learn more: Created by @MithuRheum via @RheumNow for our Rheum to Breathe: ILD Campaign #RheumTwitter #ILD #RheumX https://buff.ly/6FgDrvD https://buff.ly/6FgDrvD https://buff.ly/6FgDrvD https://buff.ly/6FgDrvD"
X Link 2025-12-26T18:01Z 25K followers, [----] engagements

"Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis The FDA has approved nerandomilast (Jascayd) a PDE4b inhibitor to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October [----]. https://buff.ly/1LeuNgN https://buff.ly/1LeuNgN"
X Link 2025-12-27T21:00Z 25.1K followers, [----] engagements

"Best of 2025: Methotrexate intolerance in rheumatoid arthritis Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however there is significant intolerance to this drug among adult RA patients - especially at doses above [--] mg per week. https://buff.ly/kcN6WkJ https://buff.ly/kcN6WkJ"
X Link 2025-12-27T23:00Z 25.1K followers, [----] engagements

"NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest results from a Phase [--] trial presented at ACR [----] sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/9yUSBWu https://buff.ly/9yUSBWu"
X Link 2025-12-29T15:00Z 25.1K followers, [---] engagements

"Rapid rituximab infusions are safe & efficient. Metanalysis of [--] RCTs [---] pts w/ autoimmune/rheumatic dz showed infusions(RTX [----] mg) of 90-120 min (w/ premedication) had low risk (3-15%) of mild (Grades [--] 2) infusion Rxns; only [--] Grade [--] Rxns https://buff.ly/vJHJbip https://buff.ly/vJHJbip"
X Link 2025-12-30T15:00Z 25.1K followers, [----] engagements

"GC dose and tapering may influence serious infection risk in patients with GCA. Discover the key safety outcomes observed during a year of JAKi therapy in a Phase [--] trial. Sponsored by AbbVie Medical Affairs +Health Impact. https://buff.ly/fRMFkjQ https://buff.ly/fRMFkjQ"
X Link 2025-12-30T21:00Z 25.1K followers, [---] engagements

"Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjgrens dz. [--] RCTs NEPTUNUS-1 and NEPTUNUS-2 met met primary endpoints w/ statistically significant improvements in disease activity in Sjgrens patients. https://buff.ly/c6COFPw https://buff.ly/c6COFPw"
X Link 2025-12-31T01:00Z 25.1K followers, [----] engagements

"BREAKING NEWS: How many patients with RA achieve and maintain remission with a JAKi Find out in the RheumNow poster hall with data from the latest real- world study of long-term RA remission. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/kzAgQIW https://buff.ly/kzAgQIW"
X Link 2026-01-02T15:01Z 25.1K followers, [---] engagements

"Sjogrens is a hot area in drug development: Sjogrens Syndrome Pipeline Insight [----] report provides comprehensive insights about 20+ companies and 22+ pipeline drugs including: nipocalimab VAY736 (ianalumab) HZN-1116 AMG [---] R-2487 https://buff.ly/ucJRICC https://buff.ly/ucJRICC"
X Link 2026-01-03T01:00Z 25.1K followers, [----] engagements

"Best of 2025: GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS the Difficult framework has now reached psoriatic arthritis (PsA). https://buff.ly/UJKZQV3 https://buff.ly/UJKZQV3"
X Link 2026-01-03T21:00Z 25.1K followers, [----] engagements

""It's suppose to be hard if it wasn't hard everyone would do it. Hard is what makes it great - Tom Hanks in "League of Their Own""
X Link 2026-01-04T15:00Z 25.1K followers, [---] engagements

"NEW FROM ACR: See data for patients with RA who achieved remission at [--] months with a JAKi and maintained response at [--] years in a real-world study. Click to learn more about long-term outcomes. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/92CpoYD https://buff.ly/92CpoYD"
X Link 2026-01-05T15:00Z 25.1K followers, [---] engagements

"JAMA teaching case: [--] yoF w/ RA Rx w/ HCQ NSAID TNFi (ETN --ADA) develops a new rash - pruritic vesicles/papular on neck mouth ears chest hands w/ some becoming ulcerated plaques ESR [---]. WHAT TO DO A) steroids; B) stop ADA; C) Benadryl or D) Read more Pt had TNFi induced lupus https://buff.ly/YdAovBb https://buff.ly/YdAovBb"
X Link 2026-01-05T16:30Z 25.1K followers, [----] engagements

"Best of 2025: [----] BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's [----] Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis psoriasis and IBD. They evaluate the effectiveness and safety of targeted therapies including strategies for switching combining tapering or withdrawing these therapies and emphasize a treat-to-target approach. These guidelines apply to adults with axSpA referring to biologic and targeted synthetic DMARDs as "targeted therapies." https://buff.ly/YElQWru https://buff.ly/YElQWru"
X Link 2026-01-06T01:00Z 25.1K followers, [----] engagements

"APP Pearls Steroids: Set a stop date upfront educate on side effects and teach "every milligram matters." Prevents dependence and eases tapering - Barbara A. Slusher MSW PA-C DFAAPA DipACLM"
X Link 2026-01-06T15:02Z 25.1K followers, [---] engagements

"Anti-mitochondrial M2 Ab (AMA-M2) in [---] IIM pts-- [--] (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of polymyositis (56% vs 23.5%) GGT alk phos levels & [--] fold more cardiac involvement (60 vs 13%) (arrhythmias CHF pulm HTN (31-56%) but no effect on survival https://buff.ly/4yVjRRC https://buff.ly/4yVjRRC"
X Link 2026-01-06T21:00Z 25.1K followers, [----] engagements

"Does GC tapering impact serious infections in patients treated with a JAKi This is your chance to see the latest 52-week safety findings from this Phase [--] study. Sponsored by AbbVie Medical Affairs + Health Impact. https://buff.ly/HwFULqs https://buff.ly/HwFULqs"
X Link 2026-01-08T21:00Z 25.1K followers, [---] engagements

"J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab FcRn blocker that reduces AutoAbs & B cell activity. Study met its [--] wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://buff.ly/IzyRtFn https://buff.ly/IzyRtFn"
X Link 2026-01-09T01:00Z 25.1K followers, [----] engagements

"Best of 2025: [----] BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's [----] Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis psoriasis and IBD. They evaluate the effectiveness and safety of targeted therapies including strategies for switching combining tapering or withdrawing these therapies and emphasize a treat-to-target approach. These guidelines apply to adults with axSpA referring to biologic and targeted synthetic DMARDs as "targeted therapies." https://buff.ly/bU8wLJc https://buff.ly/bU8wLJc"
X Link 2026-01-10T23:00Z 25.1K followers, [----] engagements

"J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab FcRn blocker that reduces AutoAbs & B cell activity. Study met its [--] wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://buff.ly/8sTzPih https://buff.ly/8sTzPih"
X Link 2026-01-11T23:00Z 25.1K followers, [----] engagements

"2025 Lancet review of Osteoarthritis did not mention/endorse Rx w/ platelet rich plasma (PRP) prompting several letters of protest. Read the authors response: Despite the popularity of PRP there are few PBO controlled high quality studies to prove its use https://buff.ly/d2YrLfd https://buff.ly/zvmsrfJ https://buff.ly/zvmsrfJ https://buff.ly/d2YrLfd https://buff.ly/zvmsrfJ https://buff.ly/zvmsrfJ"
X Link 2026-01-13T15:00Z 25.1K followers, [----] engagements

"ADJUST trial (248 JIA pts w/ Uveitis & inactive 6mos either continued or weaned off adalimumab. ADA weaning resulted in more flares (68% vs 14% mostly uveitis) w/ no protection from background DMARD Rx. Restarting ADA was mostly effective. https://buff.ly/mURKd9g https://buff.ly/mURKd9g"
X Link 2026-01-13T16:30Z 25.1K followers, [----] engagements

"BREAKING NEWS: How many patients with RA achieve and maintain remission with a JAKi Find out in the RheumNow poster hall with data from the latest real-world study of long-term RA remission. Sponsored by AbbViE Medical Affairs + Health Impact. https://buff.ly/L3JLlUO https://buff.ly/L3JLlUO"
X Link 2026-01-13T18:00Z 25.1K followers, [---] engagements

"EasyJIA score - a tool developed to refer juvenile pts w/ MSK sxs for rheum referral. [---] pts (18%) Dx w/ JIA. [--] variables (10 total points) includes large Jts daily Sxs JT swelling activity precipitating +squeeze test bending IP Jts limping/stiffness SI Pain. You need [--] points- sensitivity 95%; specificity 71%; AUC [----] https://buff.ly/gd7SUN6 https://buff.ly/gd7SUN6"
X Link 2026-01-13T21:00Z 25.1K followers, [---] engagements

"Geisinger. Medical Center (PA) has medical staff of nearly [----] and another [----] advanced practice providers (NPs PAs CRNAs midwives). They offer specialized training (eg Advanced Practitioner Fellowship in Critical Care Medicine ) and have an Advanced Practice Nursing Council https://buff.ly/EfFO4PW https://buff.ly/EfFO4PW"
X Link 2026-01-14T01:00Z 25.1K followers, [---] engagements

"Kick off with a powerhouse RA session ⚡ Drs. Elena Myasoedova Kristen Demoruelle & Jeffrey Sparks dive deep into: 📉 Mortality Trends 🧬 The Mucosal Hypothesis 🫁 Recent ILD Advances Ends with a live faculty Q&A. A cant-miss for RA clinicians in [----] 🩺 Registration still open: https://buff.ly/ILFPuhf https://buff.ly/ILFPuhf"
X Link 2026-01-14T23:30Z 25.1K followers, [----] engagements

"Retrospective single center --103 EGPA pts finds [--] (35%) w/ cardiac involvement having cardiac Sxs & biomarkers. Most common: pericarditis (77%) cardiomyopathy w/ CHF (55%) myocarditis (36%) cardiogenic shock (14%) cardiac arrest (6%) coronary v.asospasm (8%) https://buff.ly/IcvUnPr https://buff.ly/IcvUnPr"
X Link 2026-01-14T23:37Z 25.1K followers, [---] engagements

"Join us for STEP Talks at RheumNow Live Big Ideas. Real Impact. No Filler Dont miss these engaging discussions: - Placebos in Rheumatology - Dr. Andreas Kerschbaumer - Disease Modification in Osteoarthritis - Dr. Tuhina Neogi - Helicobacter pylori Update - Dr. Byron Cryer - History of Gout - Dr. Robert Terkeltaub - Asymptomatic Elevation of CK - Dr. Rohit Aggarwal - Update on Myositis Antibodies - Dr. Rohit Aggarwal Be part of the conversation and enhance your clinical thinkingattend LIVE in person https://rheumnow.live/live/65/page/830 https://rheumnow.live/live/65/page/830"
X Link 2026-01-15T19:46Z 25.1K followers, [---] engagements

"Metanalysis of [--] clinical trials [----] adults shows cannabis-based medicines (vs placebo) over 2-26 weeks are not effective in treating chronic neuropathy nerve pain regardless if given as THC of CBD. https://buff.ly/uZv0wiT https://buff.ly/uZv0wiT"
X Link 2026-01-19T13:02Z 25.1K followers, [---] engagements

"FDA & Administration are deregulating artificial intelligence & promote widespread use includes use of wearables & other AI-enabled devices. Commissioner Marty Makary updated two guidance docs defining use general wellness devices clinical decision support software https://buff.ly/be7pgva https://buff.ly/be7pgva"
X Link 2026-01-19T22:38Z 25.1K followers, [---] engagements

"Drugs that may cause toxic myopathy presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://buff.ly/TpgCwrX https://buff.ly/TpgCwrX"
X Link 2026-01-20T22:50Z 25.1K followers, [----] engagements

"Acupuncture in SpA metanalysis of [--] RCTs (2591 AS pts) showed statistically significant improvements BASDAI score BASFI score ASDAS VAS score CRP level and ESR level. Findings imited by high heterogeneity & the lack of large-scale high-quality RCTs. https://buff.ly/EQTLe6c https://buff.ly/EQTLe6c"
X Link 2026-01-23T23:30Z 25.1K followers, [----] engagements

"Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab when given to severe SLE patients had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://buff.ly/36GWcqJ https://buff.ly/36GWcqJ"
X Link 2026-01-24T23:00Z 25.1K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing